Related by context. All words. (Click for frequent words.) 75 Non Hodgkin lymphoma 72 cell lymphomas 70 Follicular lymphoma 69 DLBCL 68 lymphomas 68 follicular CD# positive 67 Non Hodgkin 67 Non Hodgkin Lymphomas 66 cell malignancies 66 leukemias 66 indolent NHL 66 chronic lymphocytic leukemia CLL 65 small lymphocytic lymphoma 65 prednisolone chemotherapy 65 CLL SLL 64 CVP cyclophosphamide vincristine 64 leukemia CLL 64 Diffuse Large B 64 Non Hodgkin Lymphoma 64 Hodgkin lymphoma HL 64 Chronic Lymphocytic Leukemia CLL 64 CHOP chemotherapy 64 CVP chemotherapy 64 cell lymphoma DLBCL 63 lymphoproliferative disorders 63 mycosis fungoides 63 relapsed refractory 63 radioimmunotherapeutic agent 63 acute leukemias 63 Leukemias 63 indolent lymphoma 63 myeloproliferative diseases 63 leukaemias 62 Chronic lymphocytic leukemia 62 follicular lymphoma 62 pediatric acute lymphoblastic 62 antigen CD# 62 renal cell carcinomas 62 Acute lymphoblastic leukemia 62 follicular lymphoma FL 62 histologic subtype 62 leukemia AML 62 multiple myeloma MM 62 relapsed indolent 62 rituximab refractory follicular 62 breast carcinomas 62 osteosarcomas 62 non Hodgkin lymphoma 62 previously untreated follicular 62 systemic lupus erythematosus SLE 62 squamous cell carcinoma SCC 62 follicular B 61 SEER database 61 histologies 61 Lymphomas 61 leukemia ALL 61 MGUS 61 TREANDA 61 adenocarcinomas 61 Ofatumumab 61 cell chronic lymphocytic 61 Cutaneous T 61 neoplasms 61 Chronic lymphocytic leukemia CLL 61 Squamous 61 RITUXAN 61 myelofibrosis polycythemia vera 61 epithelial tumors 61 nonmelanoma skin cancers 61 chronic HBV infection 61 lymphoma subtypes 61 hepatocellular carcinomas 61 lymphoid tissue 61 Follicular 61 NHLs 60 seminoma 60 HER2 overexpression 60 Cell Non Hodgkin 60 myeloproliferative neoplasms 60 Gliomas 60 subtype 60 Epratuzumab 60 MALT lymphoma 60 Acute myeloid leukemia 60 carcinoid 60 acute GvHD 60 histological subtype 60 CLL 60 Follicular Lymphoma 60 malignancies 60 cell acute lymphoblastic 60 pancreatic adenocarcinoma 60 essential thrombocythemia 59 HCV infection 59 papillary renal cell carcinoma 59 relapsed leukemia 59 lymphocytic leukemia 59 Carcinoid tumors 59 Ph + 59 non Hodgkin Lymphoma 59 invasive ductal 59 basal cell carcinoma BCC 59 colorectal cancer CRC 59 relapsed refractory aggressive 59 Gleevec resistant 59 K ras mutations 59 nonsmall cell lung cancer 59 HCV infections 59 bendamustine 59 B CLL 59 Chronic myeloid leukemia 59 subtypes 59 lung pancreatic 59 Renal cell carcinoma 59 basal cell nevus syndrome 59 haematologic 59 Non Hodgkin lymphomas 59 breast carcinoma 59 Fludarabine 59 polycythemia vera PV 59 TEAEs 59 lymphocytic 59 superficial bladder cancer 59 haematological 59 tumor xenograft models 59 myelodysplastic syndrome MDS 59 hepatocellular carcinoma HCC 59 HBeAg negative 59 Rituximab 58 bladder cancers 58 alkylating agent 58 sarcomatoid 58 colorectal carcinoma 58 Sezary syndrome 58 azacytidine 58 lenalidomide Revlimid R 58 Toxicities 58 hypereosinophilic syndrome 58 malignant lymphoma 58 HNSCC 58 nonmelanoma skin cancer 58 cervical carcinoma 58 neuroendocrine cancers 58 familial ALS 58 Anaplastic 58 Non Hodgkins lymphoma 58 DOXIL ® 58 Inflammatory bowel disease 58 thalidomide Thalomid 58 Pathway Inhibitor 58 gastrointestinal stromal tumors 58 lymphocytosis 58 chronic myelogenous leukemia CML 58 relapsed indolent NHL 58 lung carcinomas 58 common hematologic malignancy 58 imatinib Gleevec ® 58 refractory follicular 58 malignant neoplasm 58 HBeAg positive 58 Papillary 58 cutaneous T 58 relapsed MM 58 cell lymphoma ALCL 58 epithelioid 58 lymphoid malignancies 58 CYT# potent vascular disrupting 58 castrate resistant 58 medulloblastomas 58 deletion 5q 58 GISTs 58 lupus nephritis 58 T1c 58 Mantle Cell Lymphoma 58 T2DM 58 Glioblastoma Multiforme 58 lymphocyte 58 grade gliomas 58 ADPKD 58 soft tissue sarcomas 58 pheochromocytoma 58 imatinib resistant 58 Hodgkin lymphoma NHL 58 histologic subtypes 58 cell lymphoma CTCL 58 node metastases 58 cholangiocarcinoma 58 KRAS mutations occur 58 astrocytomas 58 MabThera Rituxan 58 Systemic lupus erythematosus SLE 58 serous ovarian cancer 58 vWD 58 Chronic Myelogenous Leukemia CML 58 Onco TCS 58 Herpes simplex virus 58 lymphoid 58 seminomas 58 neoplasias 57 cisplatin resistant 57 rituximab refractory 57 Decitabine 57 Metastatic breast cancer 57 HLA DR 57 cytogenetic responses 57 trans retinoic acid 57 effector function 57 follicular Non Hodgkin 57 myeloid 57 SSc 57 refractory diffuse 57 cancers 57 onset diabetes mellitus 57 SJIA 57 CHOP cyclophosphamide doxorubicin vincristine 57 subependymal giant cell 57 urothelial carcinoma 57 Medullary thyroid cancer 57 neuroendocrine tumors 57 Chronic Lymphocytic Leukemia 57 gastrointestinal stromal tumors GISTs 57 cell lymphoma 57 Glioma 57 situ CIS 57 follicular NHL 57 Rituxan rituximab 57 cyclophosphamide doxorubicin vincristine 57 cell carcinoma 57 renal cell carcinoma 57 Adjuvant chemotherapy 57 SCCHN 57 neuroblastomas 57 candidemia 57 Paraplatin ® 57 chronic GVHD 57 Soft Tissue Sarcoma 57 macroglobulinemia 57 immune thrombocytopenic purpura 57 fungoides 57 bone metastasis 57 malignant pleural mesothelioma 57 tigecycline 57 paragangliomas 57 BCG refractory 57 lobular carcinomas 57 endometrioid 57 precursor acute lymphoblastic 57 neoplastic 57 systemic juvenile idiopathic 57 Lymphocytic 57 synthetic analogues 57 advanced adenoma 57 Osteosarcoma 57 anemias 57 calcineurin inhibitors 57 nonmetastatic 57 skeletal metastases 57 Relapsed Refractory Aggressive 57 squamous cell lung cancer 57 sodium glucose cotransporter 57 pleomorphic 57 familial amyloidotic polyneuropathy FAP 57 CD# mAb 57 ovarian carcinoma 57 milatuzumab 57 follicular lymphomas 57 Sjögren syndrome 57 hematopoietic cancers 57 hematopoietic malignancies 57 carcinoid tumors 56 hepatoma 56 gastric cancers 56 heavily pretreated 56 PCNSL 56 Genentech Rituxan 56 glioblastoma multiforme GBM 56 hematologic disorders 56 T#I [002] 56 trabectedin 56 PTLD 56 PAOD 56 mucinous 56 Burkitt lymphoma 56 chronic myeloid leukemia CML 56 Myelofibrosis 56 severe neutropenia 56 YONDELIS 56 myeloproliferative 56 transthyretin amyloidosis 56 trans retinoic acid ATRA 56 Relapsed Refractory 56 gastric carcinoma 56 Relapsing remitting MS 56 MGd 56 metastatic renal cell carcinoma 56 prostate cancer CaP 56 JAK2 enzyme 56 nucleoside analogues 56 galiximab 56 recurrent glioblastoma multiforme 56 metastatic malignant 56 mediated immunity 56 differentiated thyroid 56 acute myeloid 56 atopy 56 IgA deficiency 56 prostate adenocarcinoma 56 pulmonary metastases 56 relapsing remitting 56 Amrubicin 56 imatinib Gleevec 56 Glioblastoma 56 posaconazole 56 malignant neoplasms 56 hepatocellular carcinoma 56 Polycythemia vera 56 atypical hemolytic uremic syndrome 56 Nilotinib 56 grade cervical intraepithelial 56 monocytic 56 adriamycin 56 Alemtuzumab 56 Cholangiocarcinoma 56 CMV infection 56 papillary 56 HRPC 56 neoplasm 56 Zolinza 56 Ibritumomab Tiuxetan 56 Relapsed 56 lung cancers 56 cutaneous squamous cell carcinoma 56 KRAS wild 56 Multiple Myeloma MM 56 androgen receptor AR 56 autoantibody positive 56 hepatorenal syndrome 56 gastric adenocarcinoma 56 IL 1ß 56 gastrointestinal stromal tumor 56 NSCLC 56 sporadic ALS 56 Acute myelogenous leukemia 56 erlotinib Tarceva ® 56 basal cell carcinomas 56 myeloproliferative disorders 56 Philadelphia Chromosome Positive 56 neoplasia 56 systemic lupus erythematosus 56 HBV infection 56 lobular carcinoma 56 breast pancreatic 56 relapsed mantle 56 Irinotecan 56 mCRC patients 56 juvenile idiopathic arthritis JIA 56 CD8 + 56 refractory chronic lymphocytic 56 hA# 56 Reovirus 56 mycophenolate mofetil 56 CD# CD# 56 leukemia APL 56 anaplastic 56 ALT flares 56 lung adenocarcinomas 56 Malignant mesothelioma 56 idiopathic PAH 56 GNAQ 56 receptor tyrosine kinase inhibitor 56 Personalized Immunotherapy 56 Pemetrexed 56 gastrointestinal stromal tumor GIST 56 oligodendrogliomas 56 Myelodysplastic syndromes MDS 56 medullary thyroid cancer 56 T#I mutant 56 dasatinib Sprycel 56 B lymphocyte 55 Advanced Renal Cell 55 cutaneous melanoma 55 immunodeficiency 55 post transplant lymphoproliferative 55 elevated LDH 55 NOMID 55 mTOR inhibitors 55 mesotheliomas 55 JMML 55 squamous cell carcinomas 55 Malignant Melanoma 55 GvHD 55 eosinophilic pneumonia 55 poor metabolizers 55 Interferon alfa 55 squamous 55 VEGF inhibitors 55 pilocytic astrocytomas 55 relapsed Acute Myeloid 55 cervical intraepithelial neoplasia 55 alkylating 55 BCR ABL mutations 55 benign prostatic hypertrophy BPH 55 kidney urologic 55 CD4 + CD# 55 chronic myelogenous leukemia 55 pancreatic cancers 55 immune dysregulation 55 Endometrial cancer 55 tuberous sclerosis TS 55 acute myeloid leukemia AML 55 Pancreatic neuroendocrine tumors 55 cancer mCRC 55 hematologic toxicity 55 missense mutation 55 tumoral 55 Hurthle cell 55 KRAS status 55 Hashimoto thyroiditis 55 esophageal cancers 55 ductal carcinomas 55 proliferative disorders 55 LHRH agonists 55 Gleevec imatinib mesylate 55 replicon 55 Sudhir Agrawal D.Phil 55 ductal cancer 55 Xanafide 55 hyperplastic 55 motor neuron degeneration 55 HuMax R 55 Plaque psoriasis 55 dasatinib Sprycel ® 55 Kit CD# positive 55 nephrogenic 55 B lymphocytes 55 Diabetic nephropathy 55 papillary carcinoma 55 metastatic colorectal 55 acute myelogenous leukemia AML 55 epithelial ovarian 55 clade B 55 stage IIIB 55 chronic eosinophilic leukemia 55 hamartomas 55 refractory acute myeloid 55 neurological manifestations 55 situ LCIS 55 ependymomas 55 hemolytic anemia 55 activating mutations 55 CIN2 + 55 veltuzumab 55 efalizumab 55 interferon IFN 55 herpesviruses 55 Basal cell carcinoma 55 cytopenias 55 PCa 55 metastatic neuroendocrine tumors 55 neoplastic lesions 55 HBeAg positive patients 55 induced anemia 55 germline mutations 55 Epstein Barr virus EBV 55 Waldenstrom macroglobulinemia 55 sJIA 55 mediated autoimmune diseases 55 adenomatous polyps 55 Multiple myeloma 55 BRAF V#E 55 lipid abnormalities 55 FGFR2 55 carcinoma 55 metastatic prostate 55 relapsed ovarian cancer 55 Neutropenia 55 endometrial cancers 55 Uterine fibroids 55 interleukin IL -# 55 Interferon alpha 55 FLT3 55 FOLFIRI 55 Acute myeloid leukemia AML 55 fludarabine cyclophosphamide 55 neutropenia dehydration dyspnea 55 thromboembolic disease 55 adverse reactions incidence 55 colorectal adenoma 55 leukopenia 55 pegylated liposomal doxorubicin 55 proteasome inhibitor 55 KRAS mutations 55 atypical hyperplasia 55 GnRH agonists 55 Acute lymphocytic leukemia 55 MCyR 55 low dose cytarabine 55 cervical lymph nodes 55 castration resistant 55 demyelinating diseases 55 rotavirus strains 55 anal cancers 55 hypomethylating agents 55 chlorambucil 55 invasive candidiasis 55 Squamous cell 55 pheochromocytomas 55 colorectal carcinomas 55 ccRCC 55 myelodysplastic myeloproliferative diseases 55 MAGE A3 ASCI 55 EGFR mutations 55 bexarotene 55 myelodysplastic syndromes 55 lysosomal storage diseases 55 GBM tumors 55 herpes zoster shingles 55 B Cell Lymphoma 54 mRCC 54 hypermethylated 54 neuroblastoma tumors 54 seropositive patients 54 prostate pancreatic 54 heavily pretreated patients 54 Wegener granulomatosis 54 Vidofludimus 54 hematologic 54 cabazitaxel 54 antiproliferative effects 54 missense mutations 54 chemoresistant 54 endometrial hyperplasia 54 Glioblastomas 54 alpha interferons 54 NF kB pathway 54 pancreatic NET 54 Systemic lupus 54 refractory indolent non 54 metastatic renal 54 Velcade bortezomib 54 hormone receptor positive 54 hepatic cirrhosis 54 Basal cell 54 germinal center 54 systemic anaplastic large 54 squamous cell cancers 54 alcoholic fatty liver 54 allogeneic HSCT 54 lung prostate 54 CD# antigen 54 alpha2 54 urothelial 54 SSc patients 54 progesterone receptor negative 54 Apaziquone 54 EGFR tyrosine kinase inhibitors 54 alefacept 54 chronic granulomatous disease 54 leukemic 54 testicular cancers 54 hepatitis C genotype 54 nonalcoholic steatohepatitis NASH 54 Atopic dermatitis 54 Hepatocellular Carcinoma HCC 54 peripheral blood mononuclear 54 APOL1 54 Fas ligand 54 xenograft tumors 54 chronic HBV 54 chronic periodontitis 54 V#F mutation 54 Acute Myeloid Leukaemia AML 54 Thalomid ® 54 EGFR mutant 54 autoinflammatory diseases 54 HNPCC 54 ribavirin therapy 54 Epidermal Growth Factor Receptor 54 CIN3 54 Fludara ® 54 prostate carcinoma 54 Myelodysplastic syndromes 54 lymphoma Hodgkin lymphoma 54 ErbB2 positive 54 prostate cancer PCa 54 HIV Lalezari 54 atrophic gastritis 54 IgG1 monoclonal antibody 54 pneumococcal serotypes 54 malignancy 54 Psoriatic arthritis 54 medulloblastoma 54 Rituxan MabThera 54 BRAF mutations 54 Ribavirin causes 54 Chronic myeloid leukemia CML 54 Navelbine ® 54 fluconazole resistant 54 mammary tumors 54 glioblastoma 54 leucopenia 54 mutated K ras 54 imatinib mesylate 54 Dasatinib 54 lymphocyte activation 54 adenocarcinoma 54 etoposide 54 COPAXONE ® 54 Venous thromboembolism 54 Cell Lymphoma 54 smoldering myeloma 54 hypercalcemia 54 leiomyoma 54 Glioblastoma multiforme GBM 54 Fludara 54 anthracycline containing 54 locoregional recurrence 54 ductal breast cancer 54 docetaxel Taxotere ® 54 underwent surgical resection 54 metastatic bladder 54 bronchogenic carcinoma 54 lymphoid tumors 54 invasive ductal carcinoma 54 severe hypersensitivity reactions 54 SUVmax 54 TORISEL 54 daunorubicin 54 superficial basal cell carcinoma 54 Hereditary angioedema HAE 54 Acute Myeloid Leukemia AML 54 Evoltra ® 54 FluCAM arm 54 HER2 positive metastatic breast 54 Non Hodgkins Lymphoma 54 malignant lymphomas 54 Azacitidine 54 leukemia CML 54 clinicopathologic 54 FOLFIRI alone 54 EGFR inhibitors 54 Ph + acute lymphoblastic 54 squamous cell skin 54 relapsed acute myelogenous 54 secondary hyperparathyroidism 54 distinct subtypes 54 underlying vasculopathy 54 Adenocarcinoma 54 HER2 positive breast cancer 54 cyclophosphamide methotrexate 54 CMV disease 54 K ras 54 GSTP1 54 lung cancer NSCLC 54 biologic therapy 54 invasive carcinoma 54 gliomas 54 nasopharyngeal carcinoma 54 Carcinoma 54 generalized seizures 54 gastric cardia 54 imatinib resistance 54 gene rearrangements 54 demonstrated antitumor activity 54 ANCA associated 54 diagnosed glioblastoma multiforme 54 homozygous familial hypercholesterolemia 54 metaplasia 54 dermatomyositis 54 HbF 54 Vidaza ® 54 meropenem 54 thymoma 54 hypoxia inducible factor 54 mutated KRAS gene 54 brain metastases 54 idiopathic myelofibrosis 54 Thrombocytopenia 54 KRAS mutant 54 Doxil ® 54 Dapagliflozin 54 CD# [002] 54 Voreloxin 54 JAK inhibitors 54 Inflammatory bowel diseases 54 chemotherapeutic regimens 54 thyroid cancers 54 1 diabetes T1D 54 Metastatic 54 Carboplatin 54 5-FU/LV 54 panitumumab Vectibix 54 precursor lesions 54 MYCN amplification 54 hepatitis C HCV 54 murine models 54 TEMODAL 54 IGFBP 54 ulcerative colitis UC 54 panobinostat 54 cytarabine daunorubicin 54 CaP 54 activin 54 lung colorectal 54 renal tumors 54 EGFR HER2 54 esophageal adenocarcinoma 54 febrile neutropenia 54 chronic immune thrombocytopenic 54 rituximab 54 Enbrel Humira 53 complement inhibitor eculizumab 53 ovarian lung 53 glioblastoma tumors 53 lymphoma 53 non squamous NSCLC 53 Clofarabine 53 acute lymphoblastic 53 severe oral mucositis 53 hematological 53 Glucocorticoids 53 hematologic malignancies 53 histological subtypes 53 Sutent sunitinib 53 Tindamax R 53 PNET 53 undergoing hematopoietic stem 53 Campath alemtuzumab 53 standard chemotherapy regimen 53 lymphoblastic leukemia 53 Myelodysplastic Syndrome MDS 53 anterior uveitis 53 chronic myeloid 53 myelodysplastic syndromes MDS 53 androgenetic alopecia 53 pancreatic colon 53 Pixantrone 53 intravenous bisphosphonates 53 cell adhesion molecule 53 metastatic gastric 53 adrenocortical carcinoma 53 relapsing remitting MS RRMS 53 AAT deficiency 53 anemia neutropenia 53 somatostatin analogs 53 recurrent VTE 53 hematological cancers 53 bleomycin 53 leiomyomas 53 Aplastic anemia 53 baseline LDH 53 receptor subtype 53 choriocarcinoma 53 Bezielle 53 del 5q MDS 53 mutated KRAS 53 Prostatitis 53 transplantation HCT 53 metastatic lung cancer 53 Camptosar ® 53 histone deacetylase HDAC inhibitor 53 tumor metastases 53 decompensated liver disease 53 polyarticular 53 urothelial cancer 53 syngeneic 53 hematological malignancy 53 relapsed follicular 53 epithelial cancers 53 non metastatic osteosarcoma 53 Chronic pancreatitis 53 paraganglioma 53 acute promyelocytic leukemia 53 COX2 53 NRTI resistance 53 Folfox 53 completely resected 53 chimeric monoclonal antibody 53 metastatic GIST 53 myelofibrosis MF 53 pleural mesothelioma 53 gemcitabine Gemzar ® 53 BEXXAR 53 HER2 receptor 53 gemcitabine Gemzar 53 demyelinating 53 indolent lymphomas 53 mitoxantrone chemotherapy 53 myelosuppression 53 chromosomal rearrangement 53 Chronic Myeloid Leukemia 53 diabetic nephropathy 53 carcinoids 53 Specifid 53 Kaposi sarcoma 53 interferon pathway 53 androgen deprivation 53 external genital lesions 53 chronic HCV 53 Peripheral neuropathy 53 myelomas 53 precancerous cervical lesions 53 cell carcinomas 53 colorectal lung 53 advanced adenomas 53 tipranavir ritonavir 53 Zavesca R 53 gastrointestinal cancers 53 cytogenetic response 53 ibritumomab tiuxetan 53 follicular thyroid cancer 53 LymphoStat B belimumab 53 essential thrombocythemia ET 53 HGPIN 53 DFMO 53 refractory CLL 53 ABCB1 53 colon lung 53 Severe Primary IGFD 53 ovarian breast 53 interferon alfa 53 recurrent genital herpes 53 premalignant lesions 53 Ilaris 53 nonmelanoma 53 Peginterferon alfa 2b 53 etiologic 53 NMIBC 53 leukoencephalopathy 53 haematopoietic 53 glycosylated 53 Helicobacter pylori infection 53 Atopic eczema 53 HLA B# 53 commonly mutated genes 53 Tyrosine Kinase Inhibitors 53 xenograft models 53 imipenem 53 hyperplasia 53 generalized tonic clonic seizures 53 oesophageal adenocarcinoma 53 colorectal cancers 53 Malignant gliomas 53 advanced metastatic renal 53 progressive neurodegenerative disorder 53 Ozarelix 53 Akt inhibitor 53 Irritable bowel syndrome 53 CPOP R 53 leukemias lymphomas 53 kaempferol 53 Aortic stenosis 53 idiopathic thrombocytopenic purpura 53 CTCL 53 symptomatic BPH 53 EpCAM 53 Myeloid 53 TNF antagonist 53 PsA 53 familial adenomatous polyposis 53 estrogen receptor negative 53 solar keratoses 53 antiangiogenic therapy 53 VUR 53 Cytotoxic T 53 RSV infections 53 metastatic carcinoma 53 Recurrences 53 Meningiomas 53 TGFBR1 * 6A 53 T Cell Lymphoma 53 monogenic 53 Valortim R 53 5 Fluorouracil 53 solid tumors 53 recombinant interferon 53 anthracycline taxane 53 Renal Cell Carcinoma RCC 53 immune globulin intravenous 53 refractory NSCLC 53 lumiliximab 53 chemotherapy induced neutropenia 53 SOD1 53 Lymphoma 53 gastrointestinal perforation 53 Virulizin ® 53 endometrial carcinoma 53 busulfan 53 IGFD 53 Vidaza azacitidine 53 prostate cancers 53 targeting CD# 53 System IPSS 53 Leydig cell 53 diagnosed Ph + 53 peritumoral brain edema 53 folate concentrations 53 Colorectal cancer CRC 53 childhood leukemias 53 intestinal metaplasia 53 papillary RCC 53 cystic fibrosis chronic pancreatitis 53 advanced metastatic prostate 53 HLA DRB1 * 53 erythropoietic 53 VZV 53 Juvenile Idiopathic Arthritis JIA 53 actinic keratosis 53 malignant fibrous histiocytoma 53 MabCampath 53 metastatic RCC 53 metastatic malignant melanoma 53 Kepivance 53 breast endometrial 53 nucleoside analogs 53 plus DOXIL 53 acute promyelocytic leukemia APL 53 deferiprone 53 Anthracycline 53 dexamethasone Decadron 53 pCR 53 CTAP# Capsules 53 HCV SPRINT 53 acute humoral rejection 53 steatohepatitis 53 GBMs 53 refractory multiple myeloma 53 LRP5 53 Hematologic 53 oral vancomycin 53 nonseminoma 53 chronic lymphocytic leukemia 53 Hodgkin lymphomas 53 simplex virus 53 LHRH analogues 53 azacitidine 53 refractory acute promyelocytic 53 pT3 53 recurrent ovarian cancer 53 telomere lengths 53 cisplatin carboplatin 53 idebenone 53 lymphopenia 53 paclitaxel Taxol 53 T#I mutation 53 carcinoembryonic antigen 53 factor GCSF 53 colorectal adenomas 53 papillomas 53 proliferative diabetic retinopathy 53 Neulasta ® 53 Anal cancer 53 solar keratosis 53 AEG# 53 erythema nodosum 53 Synovial sarcoma 53 cisplatin gemcitabine 53 PNH patients 53 pancytopenia 53 ofatumumab 53 DOXIL 53 squamous cell cancer 53 pituitary adenomas 53 histologically confirmed 53 bevacizumab Avastin ® 53 INVANZ 53 Cytoxan 53 Allergic rhinitis 53 systemic scleroderma 53 dacarbazine DTIC 53 pancreatic endocrine 53 tuberous sclerosis complex 53 luteinizing hormone releasing 53 operable breast cancer 53 depsipeptide 53 Crohn disease CD 53 beta interferons 53 distant metastasis 53 cytoreduction 53 melanoma basal cell 53 transgene expression 53 Estrogen Receptor 53 sunitinib Sutent ® 53 vWF 53 recombinant erythropoietin 53 CsA 53 colorectal adenocarcinoma 53 cytologically confirmed 53 mosaicism 53 coinfected 52 CCyR 52 MDR1 52 ceftazidime 52 Ceflatonin 52 sarcomas 52 taxane chemotherapy 52 premalignant 52 immune modulator 52 Etanercept